Global Idiopathic Pulmonary Fibrosis Market By Therapy (Esbriet (Pirfenidone), Ofev (Nintedanib), Tipelukast, Pamrevlumab, KD025, PRM 151, GKT831, Others); By Region (United States, EU5 (Germany, Spain, Italy, France, United Kingdom), and Japan)- Insights, Epidemiology and Forecast– 2030
The Global Idiopathic Pulmonary Fibrosis Market generated US$ 1,915.0 million in 2020 and is estimated to reach US$ 4,298.8 million by 2030, growing at a compound annual growth rate (CAGR) of 9.4%. Read More
We Are Trusted By These Great Companies!
- Published On: 30-Jul-2021 | Format:
![pdf]()
![powerpoint]()
![excel]()
| Report ID: AA0721084
| Report ID: AA0721084Request for Methodology
Base Year 2021
Historic Year 2017-2020
Forecast Year 2022-2030
No Of Pages 187
Total Figures 44
Total Tables 35
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
